Company and Stock Identity

How Tempus Connects to the Public Market

Company structure
Public company
Market access
Direct listing: Nasdaq: TEM.
Stock name
Tempus AI, Inc.
Ticker and exchange
Nasdaq: TEM
Research focus
Separate diagnostics, data licensing, applications, and AI products, then connect acquisitions and model announcements to revenue, regulatory status, and clinical use.

Tempus AI is a publicly listed precision-medicine and healthcare data company.

Dated Market Snapshot

Oct 26, 2026

Last price
$67.16
Change
-0.67%
Previous close
$67.615
52-week high / low
$93.38/$40.77
Market cap
12,193,311,370

Automated from Nasdaq. Check the exchange or investor-relations page for the current price.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Personalis SEC Form 8-K ... Regulatory record

Tempus clears antitrust review for its Personalis takeover

Personalis told the Securities and Exchange Commission that the waiting period for the Tempus mergers under the Hart-Scott-Rodino Act expired at 11:59 p.m. Eastern time on October 2, 2026. The filing notes Tempus refiled its antitrust notice on September 2, 2026, which restarted a fresh 30 day waiting period. The filing states the closing still depends on Personalis stockholder approval at a stockholders meeting plus the other closing conditions in the merger agreement. Tempus announced the deal on July 20, 2026 at 16.25 dollars per Personalis share, which it put at 1.5 billion dollars of enterprise value after counting the Tempus stake it already held, structured as an all-stock deal with the option to pay cash for up to half the shares.

Why it matters: Antitrust clearance removes the hurdle a buyer cannot control, and it leaves a shareholder vote that usually follows the board. For a health system already buying Tempus genomic reports, the useful question is what happens to Personalis NeXT Personal pricing, contracts and lab turnaround once one company owns both. Clearance is not closing, so nothing about today's ordering changes yet, and the deal could still be voted down or fail another condition.

... Tempus Investor Relations ... Investor relations

Tempus receives ARPA-H funding for an autonomous cardiology agent

Tempus said an award of up to $9.5 million will support development and prospective testing of an AI agent for heart-failure care.

Why it matters: The money is useful because it moves the agent into a prospective test instead of leaving it as a product idea. The interesting part will be how the study measures care, safety, and clinical responsibility. Until those results arrive, the award supports the program, not the outcome.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Genomics, diagnostics, data science, machine learning, clinical research, software, regulatory affairs, and commercial work.

Qualification signal: The company spans laboratory, clinical, data, and software work. Licensure or certification matters for some laboratory and clinical roles, while technical roles need production and healthcare-data evidence.

Check current roles at Tempus. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Pharmaceutical R&D, biotechnology leadership, translational science, business development, and investors
Primary use case
Identify targets, design molecules, prioritize experiments, and connect biomedical data to research decisions
Typical deployment
Ranges from software and data partnerships to platform collaborations and internally owned drug pipelines

Evidence questions

  • Which results are prospective, reproduced, and tied to a clinical or experimental endpoint?
  • How many programs are AI-originated, AI-assisted, partnered, or internally owned?
  • What has advanced beyond target identification and preclinical reporting?

Regulatory and workflow questions

  • Which entity owns development, validation, and regulatory responsibility for each program?
  • How are model-generated hypotheses reviewed before experimental or clinical use?
  • What claims are about research productivity versus a regulated product?

Data and contract questions

  • Who owns generated molecules, targets, models, and derived data?
  • Which proprietary datasets create defensibility and which are licensed?
  • Can a partner reproduce outputs and export project data after the collaboration?

Evidence and Regulation

FDA Clearances on Record

Tempus appears on 4 cleared products in the federal 510(k) record, across 3 device types.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

First-Hand Sources